Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 3c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($1.00), $0.03 worse than the analyst estimate of ($0.97).

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
• Semtech surges on strong Q2 beat and upbeat Q3 guidance
• Zoom (ZM) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance